Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor
References (27)
- et al.
Nature
(1988) - et al.
- et al.
Biochem. Biophys. Res. Commun.
(1989) - et al.
Jap. J. Pharmacol.
(1990) - et al.
Nature
(1990) - et al.
Nature
(1990) Trends Pharmacol. Sci.
(1991)- et al.
Trends Pharmacol. Sci.
(1989) - et al.
J. Cardiovasc. Pharmacol.
(1991) - et al.
Biochem. Biophys. Res. Commun.
(1991)
The Endothelins
(1990)
J. Antibiotics
(1991)
J. Antibiotics
(1991)
Cited by (930)
New insights into phenotypic switching of VSMCs induced by hyperhomocysteinemia: Role of endothelin-1 signaling
2020, Biomedicine and PharmacotherapyMetal complexes of synthetic cyclic peptides
2018, PolyhedronPathogenesis of Hypertension
2018, Hypertension: A Companion to Braunwald's Heart DiseaseThe heart as an extravascular target of endothelin-1 in particulate matter-induced cardiac dysfunction
2016, Pharmacology and TherapeuticsEndothelin Antagonism and Hypertension: An Evolving Target
2015, Seminars in NephrologyCitation Excerpt :Endothelin acts through two pharmacologically distinct G-protein–coupled receptors: endothelin A receptor (ETA) and endothelin B receptor (ETB). ETA primarily exerts vasoconstrictor and proliferative effects of ETs,23 whereas ETB induces endothelial-dependent vasodilatation through nitric oxide and prostaglandin production.24,25 Also, ETB regulates sodium and water handling in the kidney.26
Copyright © 1991 Published by Elsevier Inc.